Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Burkitt Lymphoma 25Prostatic Neoplasms 22Precursor Cell Lymphoblastic Leukemia-Lymphoma 18Lymphoma, Large B-Cell, Diffuse 16Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 10Leukemia, Biphenotypic, Acute 5Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma, B-Cell 4Plasmablastic Lymphoma 3Lymphoma, T-Cell 3Lymphoma, Follicular 3Lymphoma 3Hodgkin Disease 3Multiple Myeloma 2Melanoma 2Lymphoma, Large-Cell, Anaplastic 2Immunoblastic Lymphadenopathy 2Enteropathy-Associated T-Cell Lymphoma 2Carcinoma, Merkel Cell 2Carcinoma, Basal Cell 2Blast Crisis 2Vasculitis, Central Nervous System 1Urogenital Neoplasms 1Stiff-Person Syndrome 1Stage II Prostate Adenocarcinoma 1Rasmussen subacute encephalitis 1Polyradiculoneuropathy, Chronic Inflammatory Demyelinating 1Oropharyngeal Neoplasms 1Opsoclonus-Myoclonus Syndrome 1Neuromyelitis Optica 1

Interventions

prednylidene 1etoposide phosphate 1deltacortene 1Vincristine 1Vinblastine 1Specimen Handling 1Procarbazine 1Prednisone 1Prednisolone 1Nivolumab 1Methylprednisolone 1Magnetic Resonance Spectroscopy 1Fluorodeoxyglucose F18 1Etoposide 1Doxorubicin 1Dacarbazine 1Cyclophosphamide 1Brentuximab Vedotin 1Bleomycin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 × deltacortene × Clear all
NCT05675410 2026-06-03

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

National Cancer Institute (NCI)

Phase 3 Recruiting
1,875 enrolled
Lymphoid

Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8

Data powered by HemOnc (CC BY 4.0) Colophon âš¡